Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06122935Not ApplicableCompleted

Evaluation of the Aurora Xi New Nomogram Software 2.0

Role: lead

NCT02372877Not ApplicableCompleted

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

Role: lead

NCT01210716Phase 3Completed

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Role: lead

All 3 trials loaded